Article

Predicted Symptomatic Effectiveness of Pfizer-BioNTech BNT162b2 Vaccine Against Omicron Variant of SARS-CoV-2

2021-12-11

Abstract excerpt

This paper presents predictions of the symptomatic effectiveness of the Pfizer-BioNTech BNT162b2 (Comirnaty) vaccine against Omicron B.1.1.529, the latest SARS-CoV-2 variant of concern. They were obtained assuming fold decreases in Omicron neutralisation by vaccine-induced antibodies versus neutralisation of the virus Wild Type. A 25-fold decrease was assumed based on Omicron pseudovirus neutralisation study by Pf...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e4927a53-10ac-5b21-8a8d-46397dfc160b
DOI: 10.1101/2021.12.09.21267556

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Predicted Symptomatic Effectiveness of Pfizer-BioNTech BNT162b2 Vaccine Against Omicron Variant of SARS-CoV-2DOI 10.1101/2021.12.09.21267556Read

Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 VaccineSemantic proximity Read

Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by Antibodies induced by Vaccine alone or SARS-CoV-2 Infection plus Vaccine (Hybrid Immunity) post 6-monthsSemantic proximity Read

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serumSemantic proximity Read

Neutralization of SARS-CoV-2 Omicron pseudovirus by BNT162b2 vaccine-elicited human seraSemantic proximity Read

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variantSemantic proximity Read

Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses Against the SARS-CoV-2 Omicron Variant in Adolescents and AdultsSemantic proximity Read

Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2Semantic proximity Read

The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variantSemantic proximity Read

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infectionSemantic proximity Read

Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approachSemantic proximity Read

Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021.Semantic proximity Read

Three doses of the BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concernSemantic proximity Read